Progress in adaptive immunotherapy for cancer in companion animals

Success on the path to a cure

Katie L. Anderson, Jaime Modiano

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.

Original languageEnglish (US)
Pages (from-to)363-387
Number of pages25
JournalVeterinary Sciences
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

immunotherapy
Pets
Immunotherapy
pets
neoplasms
Neoplasms
therapeutics
immune system
Immune System
Therapeutics
immune response

Keywords

  • Adaptive immunity
  • Antibodies
  • Fas ligand
  • Immunization
  • T-lymphocytes
  • Virotherapy

Cite this

Progress in adaptive immunotherapy for cancer in companion animals : Success on the path to a cure. / Anderson, Katie L.; Modiano, Jaime.

In: Veterinary Sciences, Vol. 2, No. 4, 01.12.2015, p. 363-387.

Research output: Contribution to journalReview article

@article{c6097b65ee9542618d5e372433b058df,
title = "Progress in adaptive immunotherapy for cancer in companion animals: Success on the path to a cure",
abstract = "Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.",
keywords = "Adaptive immunity, Antibodies, Fas ligand, Immunization, T-lymphocytes, Virotherapy",
author = "Anderson, {Katie L.} and Jaime Modiano",
year = "2015",
month = "12",
day = "1",
doi = "10.3390/vetsci2040363",
language = "English (US)",
volume = "2",
pages = "363--387",
journal = "Veterinary Sciences",
issn = "2306-7381",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Progress in adaptive immunotherapy for cancer in companion animals

T2 - Success on the path to a cure

AU - Anderson, Katie L.

AU - Modiano, Jaime

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.

AB - Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.

KW - Adaptive immunity

KW - Antibodies

KW - Fas ligand

KW - Immunization

KW - T-lymphocytes

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85001970249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001970249&partnerID=8YFLogxK

U2 - 10.3390/vetsci2040363

DO - 10.3390/vetsci2040363

M3 - Review article

VL - 2

SP - 363

EP - 387

JO - Veterinary Sciences

JF - Veterinary Sciences

SN - 2306-7381

IS - 4

ER -